MERCK KGAA WINS FIRST ERBITUX APPROVAL FOR HEAD CANCER

A A

Germany's Merck KGaA has won Swiss approval to market cancer drug Erbitux for treating head and neck cancer in combination with radiation therapy, the company said on Thursday. "This is the first approval for Erbitux for the treatment of head and neck cancer anywhere in the world," Merck said in a statement.

Reuters (http://today.reuters.com/business/newsArticle.aspx?type=health&storyID=nL22554917)